David Ochoa
Target discovery | Computational Biology | Human Disease Genetics | ML | Cloud computing - @opentargets.org
- @ebi.embl.org
- The needle in the haystack problem: spotting novel drug targets among redundant evidence. Our solution? A time-series novelty metric for Open Targets Platform associations. Thanks to Coté Falaguera & @opentargets.org partners for making this happen.
- 🚀 Announcing the Official @opentargets.org MCP! We've partnered with @anthropic.com to give AI seamless access to high-quality genetic and target-discovery data. Open for the entire community to accelerate therapeutic development. Read more at blog.opentargets.org/official-ope...
- What a ride so far… 🎂
- #OnThisDay 10 years ago, we launched the Open Targets Platform! 🎂 🧬🖥️
- Reposted by David OchoaA project many years in the process, we’re pleased to present our work on multi-ancestry meta-analysis across a boatload of traits in the UK Biobank: www.nature.com/articles/s41...
- If you care about regulatory variants don’t miss the E2G extension of the @opentargets.org Platform. There are synergies that only a fully open science allows and this is a good one!
- Excited for a major milestone in our efforts to map enhancers and interpret variants in the human genome: The E2G Portal! e2g.stanford.edu This collates our predictions of enhancer-gene regulatory interactions across >1,600 cell types and tissues. Uses cases 👇 1/
- Reposted by David Ochoa🚨New preprint just dropped 🚨 medrxiv.org/content/10.1101/2025.06.24.25330216 The main output from my PhD is finally public and we’re SUPER excited about the findings! If you’re interested in what we learnt about IBD with a massive 700+ sample sc-eQTL dataset of the gut, read on!
- 🚀 The Summer ☀️ @opentargets.org Platform release is here! If you thought the last update was big… just wait till you see what’s inside. A quick thread on the highlights 👇
- Reposted by David OchoaOur new contribution to the quest to find causal GWAS genes! Sam Ghatan from my lab at @nygenome.org led a systematic comparison of eQTLs and CRISPRi+scRNA-seq screens. TL;DR: they provide highly complementary insights, with ortogonal pros and cons. 🧵👇 www.biorxiv.org/content/10.1...
- Reposted by David Ochoa[Not loaded yet]
- Big thanks to the community for the great feedback we are receiving on the spring @opentargets.org Platform release. There are many positive and new ideas for improving our scientific interpretation and products. Feedback is a critical aspect of an open project's lifecycle. Please keep it coming 🧬🖥️
- Reposted by David Ochoa🚀 Big news! We've just published the official guidelines for submitting affinity proteomics data to PRIDE @pride-ebi.bsky.social (supported technologies Olink & SomaScan)! Get ahead of the curve—check them out & start your submissions! 👇 🔗 github.com/PRIDE-Archiv... #Proteomics #Olink #SomaScan
- The @opentargets.org Platform Spring 🌼 release brings a step-change in how we address common disease genetics. We included the results of a large-scale analysis on GWAS and functional genomics studies to inform target selection further 🧬 👩💻 blog.opentargets.org/a-step-chang...
- From next spring, the Open Targets Platform will incorporate the best of Open Targets Genetics into an integrated drug discovery platform 🧵
- The update will include a refreshed post-GWAS analysis covering state-of-the-art data and methodologies, resulting on 2.5M GWAS and molQTL credible sets, colocalisation analysis and L2G predictions
- Reposted by David OchoaWhat do GWAS and rare variant burden tests discover, and why? Do these studies find the most IMPORTANT genes? If not, how DO they rank genes? Here we present a surprising result: these studies actually test for SPECIFICITY! A 🧵on what this means... (🧪🧬) www.biorxiv.org/content/10.1...
- Reposted by David OchoaSpecificity, length, and luck: How genes are prioritized by rare and common variant association studies biorxiv.org/content/10.1101/202…
- Reposted by David Ochoa[Not loaded yet]
- In the upcoming NAR issue, we summarise the last 2 years of updates in the @opentargets.org Platform. One step at a time... academic.oup.com/nar/advance-...
- Reposted by David Ochoa[Not loaded yet]
- crispy morning in the genome campus…
- plain and simple 👌
- Moving day at @opentargets.org It always amazed me the UK ability to appreciate remarkable scientists. The new @ebi.embl.org building couldn’t be named after a more inspirational figure
- Reposted by David OchoaMy group's work dissecting the contribution of common variants to rare neurodevelopmental conditions is now out at nature.com/articles/s41..., led by co-first authors Qinqin Huang (not yet on blue sky) and @emiliewigdor.bsky.social . See below for Emilie's tweetorial.
- 📣 Big news! Our tag-team effort on common variants in rare neurodevelopmental conditions is now out in Nature 📣 Co-first authoring with the brilliant Qinqin Huang🌟—proof that teamwork does make the dream work. 💪 www.nature.com/articles/s41...
- Reposted by David OchoaResharing here a recent X post. In this preprint, we introduce an improved version of NanoSeq, a duplex sequencing protocol with <5 errors per billion bp in single DNA molecules, and use it to study the somatic mutation landscape of oral epithelium in >1000 people. 1/ www.medrxiv.org/content/10.1...
- To complete the healing it would be good to start thinking who are we missing here 🦋
- Reposted by David Ochoa[Not loaded yet]
- Reposted by David Ochoa[Not loaded yet]
- Reposted by David Ochoa[Not loaded yet]
